Business
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer
4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to TherapyNEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-profile study is evalu
About this update from Gilead Sciences, Inc.
[{"type":"image","alt":"4D Path","displaySize":"","headline":null,"caption":"4D Path","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":131,"url":"https://media.zenfs.com/en/globenewswire.com/e7ded60b3399fc923d4f505541a106c3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KSUneWWfWw4i.._wLEcrbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e7ded60b3399fc923d4f505541a106c3","width":300,"height":131}},"lazy":false},{"type":"text","content":"4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to Therapy","length":75,"tagName":"p"},{"type":"text","content":"NEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-profile study is evaluating a novel combination therapy for patients with locally advanced or metastatic urothelial carcinoma (mUC), including bladder cancer, and represents an important step forward in 4D Path’s mission to redefine precision oncology.","length":655,"tagName":"p"},{"type":"text","content":"The DAD-IO study builds upon the successful Phase I Double Antibody Drug Conjugate (DAD) trial, examining a regimen that combines two powerful Antibody Drug Conjugates (ADC)—Sacituzumab Govitecan (SG, from Gilead) and Enfortumab Vedotin (EV, from Seagen/Astellas)—with or without the immune checkpoint inhibitor Pembrolizumab. This approach is being studied in both treatment-naïve patients (SG+EV+Pembrolizumab) and those who have progressed on prior therapies (SG+EV).","length":470,"tagName":"p"},{"type":"text","content":"As part of the study, 4D Path will analyze pre-treatment H&E-stained biopsy slides using its proprietary Q-Plasia OncoReader™ (QPOR™) platform. By applying physics-based algorithms to whole-slide images, QPOR will generate predictive biomarkers linked to immune response, cell proliferation, and key patterns of tumor biology, helping to anticipate how patients may respond to this new combination therapy.","length":420,"tagName":"p"},{"type":"text","content":"“The responses we hav...